HL237 clinical trials
Also written HL237.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How each study uses HL237 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses HL237 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Phase 2a Clinical Trial of HL237 for Rheumatoid ArthritisStatus unknownPhase 2Hanlim Pharm. Co., Ltd.NCT04638426Written as HL237 tablet
- The Study of Pharmacokinetic Interactions Between HL237 and TacrolimusStatus unknownPhase 1Hanlim Pharm. Co., Ltd.NCT04633733Written as HL237 tablet
- A Multiple Dose of HL237 in Healthy Male SubjectStatus unknownPhase 1Hanlim Pharm. Co., Ltd.NCT03896594Written as HL237
- A Single Ascending Dose Clinical Trial to Find the Maximum Tolerable Dose of HL237 in Healthy Male SubjectCompletedPhase 1Hanlim Pharm. Co., Ltd.NCT03278470Written as HL237